AMA approves CPT code for Axxent electronic brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

AMA approves CPT code for Axxent electronic brachytherapy

FREMONT, California—Xoft, Inc., maker of the FDA-approved Axxent Electronic Brachytherapy System (see Oncology NEWS International, June 2007, page 34) has announced that Axxent treatment now has a CPT reimbursement code. The American Medical Association CPT Editorial Panel approved the code (Category III CPT Code 0182T) for this novel form of high-dose-rate radiation therapy for the treatment of early-stage breast cancer. The code has been assigned a New Technology Ambulatory Payment Classification (APC), which secures payment for Medicare recipients who receive the treatment in the hospital outpatient setting.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Related Content